Testing a new gene therapy for geographic atrophy in older adults
Part of Eyes & vision clinical trials.
This trial tests a new treatment called PST-611, a non-viral gene therapy given as an injection into the eye. It is for people aged 65 and older with a specific type of advanced dry age-related macular degeneration (AMD) called geographic atrophy, which has been getting worse over the past year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years or older.
- You must have geographic atrophy (a type of dry AMD) that has grown at least 1.6 mm² per year recently.
- The area of geographic atrophy in the study eye must be between 1.25 mm² and 16 mm².
- Your vision in the study eye should be 20/32 or worse (less than 75 letters on a reading chart).
- You cannot have had any eye surgery or infection in the past 12 weeks, and no more than 2 anti-VEGF injections per year are allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This trial tests a single gene therapy injection (AGX-08) for people with advanced geographic atrophy, a severe form of age-related macular degeneration that causes vision loss. It aims to see if the treatment is safe and can slow down further damage.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.